The immuno-oncology drug Keytruda’s sales have been skyrocketing in the domestic drug market. In the first half of the year alone, the drug posted sales of over KRW 200 billion and secured its unrivaled lead in the market. The drug’s sales have been rising more steeply after the drug’s reimbursement was extended as first-line therapy last year.

According to the market research institution IQVIA on the 24th, MSD Korea’s Keytruda posted the most sales, recording KRW 183.8 billion in 1H last year. With a 94.7% increase from the KRW 94.4 billion it had posted last year, the drug maintained its lead in the market. Keytruda posted sales of KRW 88.8 billion in Q1, which was a 117.1% YoY increase, followed by